Kura Oncology (NASDAQ:KURA) Stock Rating Upgraded by StockNews.com

Kura Oncology (NASDAQ:KURA) was upgraded by stock analysts at StockNews.com from a “sell” rating to a “hold” rating in a research report issued on Thursday.

Several other equities research analysts also recently weighed in on the company. JMP Securities reiterated a “market outperform” rating and issued a $28.00 price target on shares of Kura Oncology in a report on Thursday, February 6th. Wedbush reiterated an “outperform” rating and issued a $36.00 price target on shares of Kura Oncology in a report on Thursday. Cantor Fitzgerald restated an “overweight” rating on shares of Kura Oncology in a report on Monday, December 9th. Scotiabank reduced their price objective on Kura Oncology from $18.00 to $10.00 and set a “sector perform” rating on the stock in a report on Wednesday, January 8th. Finally, TD Cowen restated a “buy” rating on shares of Kura Oncology in a report on Thursday, November 21st. Four investment analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Kura Oncology currently has a consensus rating of “Moderate Buy” and an average target price of $27.13.

Kura Oncology Trading Up 0.8 %

Shares of NASDAQ KURA opened at $7.71 on Thursday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.47 and a current ratio of 11.47. The business’s 50 day moving average price is $8.16 and its 200-day moving average price is $13.88. Kura Oncology has a fifty-two week low of $6.98 and a fifty-two week high of $24.17. The company has a market cap of $599.56 million, a price-to-earnings ratio of -3.27 and a beta of 0.78.

Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings results on Wednesday, February 26th. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.65) by $0.43. The business had revenue of $53.88 million during the quarter, compared to analysts’ expectations of $57.96 million. On average, sell-side analysts expect that Kura Oncology will post -2.44 earnings per share for the current year.

Insider Activity

In other news, insider Mollie Leoni sold 4,963 shares of Kura Oncology stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $39,058.81. Following the transaction, the insider now directly owns 88,253 shares in the company, valued at approximately $694,551.11. This trade represents a 5.32 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, SVP Thomas James Doyle sold 4,949 shares of Kura Oncology stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $38,948.63. Following the completion of the transaction, the senior vice president now owns 88,193 shares in the company, valued at $694,078.91. This represents a 5.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 11,729 shares of company stock worth $92,307. 5.50% of the stock is currently owned by company insiders.

Institutional Trading of Kura Oncology

A number of institutional investors have recently made changes to their positions in the business. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Kura Oncology by 7.4% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 131,718 shares of the company’s stock worth $1,147,000 after purchasing an additional 9,050 shares in the last quarter. Woodline Partners LP boosted its position in shares of Kura Oncology by 20.6% in the 4th quarter. Woodline Partners LP now owns 172,704 shares of the company’s stock worth $1,504,000 after purchasing an additional 29,497 shares in the last quarter. Velan Capital Investment Management LP acquired a new stake in shares of Kura Oncology in the 4th quarter worth $1,306,000. Squarepoint Ops LLC acquired a new stake in shares of Kura Oncology in the 4th quarter worth $799,000. Finally, Two Sigma Advisers LP boosted its position in shares of Kura Oncology by 147.1% in the 4th quarter. Two Sigma Advisers LP now owns 242,200 shares of the company’s stock worth $2,110,000 after purchasing an additional 144,201 shares in the last quarter.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.